PRKCD (Ab-64) Antibody

What is PRKCD (Ab-64) Antibody and what does it target?

PRKCD (Ab-64) Antibody is a polyclonal antibody that specifically recognizes protein kinase C delta (PRKCD) around the phosphorylation site of tyrosine 64. The antibody targets the synthetic non-phosphopeptide derived from human PKCD around the phosphorylation site of tyrosine 64 (H-I-Y(p)-E-G) . This antibody is particularly useful for detecting endogenous levels of PRKCD when phosphorylated at this specific residue, making it valuable for studying post-translational modifications of the PRKCD protein in various signaling pathways.

What are the validated applications for PRKCD (Ab-64) Antibody?

PRKCD (Ab-64) Antibody has been validated for the following applications:

The antibody has been tested with human and mouse samples, with consistent results observed across multiple experimental conditions .

What is the biological significance of PRKCD and its phosphorylation at Tyr64?

PRKCD is a calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase with a molecular weight of approximately 78 kDa . It plays critical roles in:

• Regulation of apoptosis (can function as either pro-apoptotic or anti-apoptotic depending on context)

• B cell proliferation and tolerance induction

• Cell survival in certain cancer types

• Oxygen radical production by NADPH oxidase

• Platelet functional responses

Phosphorylation at Tyr64 is one of the post-translational modifications that can regulate PRKCD activity and function. Tyrosine phosphorylation of PRKCD can affect its subcellular localization, including translocation to the mitochondria during apoptotic stimulation .

How should PRKCD (Ab-64) Antibody be stored for optimal performance?

For long-term storage, maintain the antibody at -20°C for up to one year . For frequent use and short-term storage (up to one month), storage at 4°C is recommended. Avoid repeated freeze-thaw cycles as they can degrade antibody quality and performance. Many commercial versions of the antibody are supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide as stabilizers .

How should I design a Western blot experiment to detect phosphorylated PRKCD at Tyr64?

For optimal Western blot detection of phosphorylated PRKCD at Tyr64, follow these methodological steps:

• Sample preparation:

  • Extract total protein using a lysis buffer containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) to preserve phosphorylation status

  • Determine protein concentration using Bradford or BCA assay

  • Prepare 20-40 μg of total protein per lane

• Gel electrophoresis and transfer:

  • Use 8-10% SDS-PAGE (PRKCD has a molecular weight of approximately 77-78 kDa)

  • Transfer to PVDF membrane (preferred over nitrocellulose for phospho-proteins)

• Blocking and antibody incubation:

  • Block membrane with 5% BSA in TBST (not milk, which contains phosphatases)

  • Incubate with PRKCD (Ab-64) Antibody at 1:500-1:3000 dilution overnight at 4°C

  • Wash thoroughly with TBST (3-5 times, 5-10 minutes each)

  • Incubate with appropriate HRP-conjugated secondary antibody

• Controls to include:

  • Positive control: Lysate from cells treated with pervanadate or EGF to induce tyrosine phosphorylation

  • Negative control: Lysate treated with lambda phosphatase

  • Loading control: Anti-total PRKCD or housekeeping protein

Positive Controls:

• Cell lysates from pervanadate-treated cells (broad-spectrum tyrosine phosphatase inhibitor)

• Cells treated with stimuli known to induce PRKCD phosphorylation (e.g., PMA, H₂O₂, or UV irradiation)

• Recombinant phosphorylated PRKCD protein (if available)

Negative Controls:

• Samples treated with lambda phosphatase to remove phosphorylation

• Cell lysates from PRKCD knockout cell lines

• Blocking peptide competition experiments using the specific immunogenic peptide

• Isotype control antibody to detect non-specific binding

Including these controls helps validate antibody specificity and ensures that observed signals represent genuine phosphorylated PRKCD rather than non-specific binding .

How can I optimize immunostaining experiments using PRKCD (Ab-64) Antibody?

For immunocytochemistry (ICC) or immunofluorescence (IF) experiments:

• Fixation and permeabilization:

  • Test both PFA (4%) and methanol fixation methods as phospho-epitopes may be sensitive to fixation method

  • Permeabilize with 0.1-0.3% Triton X-100 in PBS for 10 minutes

• Blocking:

  • Use 5-10% normal serum (from the species of secondary antibody) with 1% BSA

• Antibody incubation:

  • Dilute primary antibody 1:50-1:300 in blocking buffer

  • Incubate overnight at 4°C in a humidified chamber

  • Wash 3x with PBS

  • Incubate with fluorophore-conjugated secondary antibody

• Controls and counterstaining:

  • Include phosphatase-treated negative controls

  • Use nuclear counterstain (DAPI) for orientation

  • Consider co-staining with markers of subcellular compartments to track PRKCD localization

How can I use PRKCD (Ab-64) Antibody to investigate the role of PRKCD in autoimmune diseases?

Research has linked mutations in PRKCD with autoimmune diseases, particularly a syndrome characterized by chronic lymphadenopathy, splenomegaly, autoantibodies, and NK cell dysfunction . To investigate these connections:

• Patient sample analysis:

  • Compare PRKCD phosphorylation levels between patients with autoimmune conditions and healthy controls

  • Correlate phosphorylation status with clinical parameters and disease severity

• Functional studies:

  • Isolate B cells from patients and controls

  • Use the antibody to monitor PRKCD phosphorylation following B-cell stimulation

  • Correlate phosphorylation with B-cell proliferation, apoptosis, and antibody production

• Genetic association studies:

  • Examine PRKCD phosphorylation in cells harboring disease-associated variants

  • Create table comparing phosphorylation status across different genetic backgrounds:

  Genetic Background	Baseline Phospho-Tyr64 PRKCD	Induced Phospho-Tyr64 PRKCD	B-cell Proliferation Rate
  Wild-type	Low	High (following stimulation)	Normal
  Disease-associated variants	Variable	Impaired response	Elevated
  PRKCD knockout	None	None	Significantly elevated

• Intervention studies:

  • Use the antibody to monitor changes in PRKCD phosphorylation following therapeutic interventions

  • Track correlation between treatment response and phosphorylation status

What are the methodological considerations when using PRKCD (Ab-64) Antibody in multiplex assays?

When incorporating PRKCD (Ab-64) Antibody into multiplex assays such as cytometric bead arrays or multiplex imaging applications:

• Antibody pairs selection:

  • Verify compatibility with other antibodies in the panel

  • For capture-detection pairs, select antibodies recognizing different epitopes

  • Consider using predefined matched pairs such as Proteintech's 84261-1-PBS (capture) and 84261-4-PBS (detection)

• Conjugation considerations:

  • Use antibodies in conjugation-ready formats (PBS only, BSA and azide-free)

  • Verify antibody concentration (typically 1 mg/mL) prior to conjugation

  • Follow manufacturer's protocol for conjugation to fluorophores, biotin, or beads

• Validation of multiplex assays:

  • Perform single-plex assays first to establish baseline performance

  • Test for cross-reactivity between antibodies in the panel

  • Include appropriate controls for each marker

  • Validate with spike-recovery experiments using known quantities of phosphorylated PRKCD

• Data analysis:

  • Implement appropriate gating strategies

  • Correct for spectral overlap when using multiple fluorophores

  • Apply statistical methods accounting for multiple comparisons

How can I use PRKCD (Ab-64) Antibody to study PRKCD's role in mitophagy and mitochondrial function?

Recent research has identified PRKCD as a positive regulator of PRKN-independent mitophagy . To investigate this function:

• Colocalization studies:

  • Use PRKCD (Ab-64) Antibody alongside mitochondrial markers

  • Track PRKCD phosphorylation at Tyr64 during mitophagy induction

  • Quantify colocalization using confocal microscopy and Pearson's correlation coefficient

• Functional mitophagy assays:

  • Monitor mitochondrial clearance in cells with varying levels of phosphorylated PRKCD

  • Use mitophagy inducers such as CCCP or DFP alongside PRKCD kinase inhibitors

  • Quantify mitophagy events using flow cytometry or high-content imaging

• Biochemical fractionation:

  • Isolate mitochondrial fractions and analyze phospho-PRKCD content

  • Compare phosphorylation status before and after mitophagy induction

  • Perform immunoprecipitation to identify mitochondrial binding partners

• CRISPR-based approaches:

  • Create Tyr64-to-Phe mutants to prevent phosphorylation

  • Use the antibody to verify absence of phosphorylation

  • Compare mitophagy efficiency between wild-type and mutant cells

Why might I observe inconsistent results when using PRKCD (Ab-64) Antibody in Western blots?

Several factors can contribute to inconsistent Western blot results:

• Phosphorylation status preservation:

  • Insufficient phosphatase inhibitors in lysis buffer

  • Sample degradation during processing

  • Delayed freezing of samples after collection

  Solution: Use freshly prepared RIPA buffer with phosphatase inhibitor cocktails. Process samples quickly and store at -80°C immediately.

• Technical variables:

  • Inconsistent transfer efficiency

  • Inadequate blocking leading to high background

  • Secondary antibody cross-reactivity

  Solution: Use stain-free technology to verify transfer efficiency. Optimize blocking conditions (5% BSA generally works better than milk for phospho-antibodies).

• Antibody-specific issues:

  • Lot-to-lot variability in polyclonal antibodies

  • Degradation due to improper storage or handling

  • Non-specific binding to similar phospho-epitopes

  Solution: Validate each new lot with positive controls. Consider recombinant monoclonal alternatives for consistency .

How can I determine if changes in PRKCD phosphorylation at Tyr64 are biologically significant?

To establish biological significance of changes in PRKCD Tyr64 phosphorylation:

• Quantitative assessment:

  • Normalize phospho-PRKCD signal to total PRKCD protein

  • Use appropriate statistical tests with adequate sample sizes (n≥3)

  • Consider fold-change thresholds based on literature (typically ≥1.5-fold)

• Temporal dynamics:

  • Track phosphorylation changes over multiple time points

  • Correlate with downstream signaling events and cellular outcomes

  • Use phospho-specific inhibitors to block the signal and observe consequences

• Functional correlation:

  • Pair phosphorylation data with functional assays (e.g., apoptosis, proliferation)

  • Use site-directed mutagenesis (Y64F) to prevent phosphorylation

  • Compare phenotypes between phospho-mimetic (Y64E) and phospho-dead mutants

• Systems biology approach:

  • Contextualize Tyr64 phosphorylation within broader signaling networks

  • Consider multiple phosphorylation sites on PRKCD simultaneously

  • Use pathway analysis tools to identify affected cellular processes

Sources of False Positives:

• Cross-reactivity with other PKC isoforms (particularly those with similar phosphorylation sites)

• Non-specific binding to similar phospho-tyrosine motifs in other proteins

• Insufficient blocking or washing steps in protocols

• Secondary antibody binding to Fc receptors in certain cell types

• Sample contamination with exogenous phosphatases or kinases

Sources of False Negatives:

• Loss of phosphorylation during sample preparation (insufficient phosphatase inhibitors)

• Epitope masking due to protein-protein interactions or conformational changes

• Suboptimal antibody concentration or incubation conditions

• Low abundance of phosphorylated protein below detection threshold

• Improper primary-secondary antibody pairing or detection system

Methodological solutions:

• Validate antibody specificity using knockout/knockdown controls

• Include phosphatase-treated negative controls

• Use blocking peptides to confirm signal specificity

• Optimize sample preparation to preserve phosphorylation

• Consider alternative detection methods (e.g., enhanced chemiluminescence vs. fluorescence)

How can I design experiments to study the temporal dynamics of PRKCD Tyr64 phosphorylation during cellular stress responses?

To effectively capture phosphorylation dynamics during stress responses:

• Time-course experimental design:

  • Select appropriate stress stimuli (e.g., oxidative stress with H₂O₂, DNA damage with etoposide)

  • Collect samples at multiple time points (0, 5, 15, 30, 60, 120, 240 minutes)

  • Process samples simultaneously to minimize technical variability

• Quantitative analysis approaches:

  • Perform Western blots with both phospho-specific and total PRKCD antibodies

  • Calculate phosphorylation ratio (phospho/total) at each time point

  • Generate time-course curves with statistical analysis of replicates (n≥3)

  Time (min)	Phospho-PRKCD/Total PRKCD Ratio	Subcellular Localization	Downstream Marker Activation
  0	Baseline value	Primarily cytoplasmic	Minimal
  5	Rapid increase	Beginning translocation	Initiation
  15	Peak value	Nuclear/mitochondrial	Strong activation
  30	Plateau or decline	Variable	Sustained/declining
  60+	Return to baseline or new state	Redistributing	Resolution phase

• Complementary approaches:

  • Live-cell imaging with phospho-sensors if available

  • Flow cytometry for single-cell resolution of phosphorylation events

  • Phosphoproteomics to contextualize Tyr64 with other phosphorylation sites

  • Biochemical fractionation to track subcellular localization changes

How can I implement Design of Experiments (DOE) methodology to optimize PRKCD (Ab-64) Antibody use in my research?

Implementing DOE methodology can systematically optimize antibody performance:

• Identify key variables (factors) affecting antibody performance:

  • Antibody concentration (dilution factor)

  • Incubation time and temperature

  • Blocking buffer composition

  • Washing stringency

  • Sample preparation method

• Design an experimental matrix:

  • Use software like MODDE® to create a factorial or response surface design

  • Include center points for robustness assessment

  • Consider interactions between factors

• Define measurable responses:

  • Signal-to-noise ratio

  • Limit of detection

  • Coefficients of variation

  • Background levels

  • Positive control signal intensity

• Execute experiments and analyze results:

  • Run experiments in randomized order

  • Use statistical tools to identify significant factors

  • Generate response surfaces to identify optimal conditions

  • Validate optimal conditions with confirmatory experiments

• Create standardized protocol based on optimal conditions:

  • Document detailed methodology

  • Assess robustness across different operators and equipment

  • Implement regular quality control procedures

What methodological approaches can I use to study the relationship between PRKCD Tyr64 phosphorylation and B-cell dysfunction in autoimmune disorders?

Building on evidence linking PRKCD mutations with autoimmune disorders , a comprehensive methodological approach includes:

• Patient-derived samples analysis:

  • Isolate B cells from patients with PRKCD mutations/polymorphisms and healthy controls

  • Compare baseline and stimulation-induced Tyr64 phosphorylation

  • Correlate with clinical parameters and disease severity

• Functional characterization workflow:

  • Measure B-cell proliferation (CFSE dilution assay)

  • Assess apoptosis (Annexin V/PI staining)

  • Evaluate antibody production (ELISA)

  • Analyze autoreactive B-cell frequency (antigen-specific staining)

• Genetic manipulation approaches:

  • Generate CRISPR-edited cells with disease-associated PRKCD variants

  • Create phospho-mimetic (Y64E) and phospho-dead (Y64F) mutants

  • Develop inducible expression systems for temporal control

  • Perform rescue experiments in patient-derived cells

• Integration with signaling pathway analysis:

  • Investigate upstream regulators of Tyr64 phosphorylation

  • Map downstream effectors using phospho-proteomics

  • Identify potential therapeutic targets for intervention

  • Test pathway-specific inhibitors to modulate B-cell function

This comprehensive approach combines clinical samples, functional assays, and molecular techniques to establish causal relationships between PRKCD phosphorylation, B-cell function, and autoimmune pathogenesis .